Preliminary study of chemosensitivity tests in osteosarcoma using a histoculture drug response assay

By Soo Yong Lee, Dae Geun Jeon, Wan Hyung Cho, Won Seok Song, Moon Bo Kim, Jong Hoon Park

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: The clinical efficacy of chemotherapy is strongly correlated with the histoculture drug response assay (HDRA) in various types of cancers. However, there have been no previous reports on its use in osteosarcoma. Materials and Methods: Thirty-six fresh samples of human osteosarcoma were evaluated by the HDRA method in order to determine its possible usefulness in the treatment of this cancer. All the materials were obtained either during biopsy or surgical excision at our hospital, between January 2003 and October 2005. Results: A significant inhibition rate in primary biopsies was observed with Adriamycin (ADM) (47.3±15.3%); Cisplatin (CDDP) (36.3±22.3%); and Carboplatin (CBP) (50.5±23.3%); treatment. ADM and CBP demonstrated a statistically significant increase in inhibition rates compared to the other drugs. Conclusion: Even though the HDRA method has many limitations, it might be a feasible and useful technique for selecting and predicting the efficacy of anticancer drugs for osteosarcoma patients.

Original languageEnglish
Pages (from-to)2929-2932
Number of pages4
JournalAnticancer Research
Volume26
Issue number4 B
Publication statusPublished - 2006 Jul 1
Externally publishedYes

Fingerprint

Osteosarcoma
Pharmaceutical Preparations
Carboplatin
Doxorubicin
Biopsy
Cisplatin
Neoplasms
Drug Therapy
Therapeutics

Keywords

  • Chemosensitivity
  • Histoculture drug response assay
  • Osteosarcoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Lee, B. S. Y., Jeon, D. G., Cho, W. H., Song, W. S., Kim, M. B., & Park, J. H. (2006). Preliminary study of chemosensitivity tests in osteosarcoma using a histoculture drug response assay. Anticancer Research, 26(4 B), 2929-2932.

Preliminary study of chemosensitivity tests in osteosarcoma using a histoculture drug response assay. / Lee, By Soo Yong; Jeon, Dae Geun; Cho, Wan Hyung; Song, Won Seok; Kim, Moon Bo; Park, Jong Hoon.

In: Anticancer Research, Vol. 26, No. 4 B, 01.07.2006, p. 2929-2932.

Research output: Contribution to journalArticle

Lee, BSY, Jeon, DG, Cho, WH, Song, WS, Kim, MB & Park, JH 2006, 'Preliminary study of chemosensitivity tests in osteosarcoma using a histoculture drug response assay', Anticancer Research, vol. 26, no. 4 B, pp. 2929-2932.
Lee, By Soo Yong ; Jeon, Dae Geun ; Cho, Wan Hyung ; Song, Won Seok ; Kim, Moon Bo ; Park, Jong Hoon. / Preliminary study of chemosensitivity tests in osteosarcoma using a histoculture drug response assay. In: Anticancer Research. 2006 ; Vol. 26, No. 4 B. pp. 2929-2932.
@article{7a0d178f6c6647bf827e834c44551234,
title = "Preliminary study of chemosensitivity tests in osteosarcoma using a histoculture drug response assay",
abstract = "Background: The clinical efficacy of chemotherapy is strongly correlated with the histoculture drug response assay (HDRA) in various types of cancers. However, there have been no previous reports on its use in osteosarcoma. Materials and Methods: Thirty-six fresh samples of human osteosarcoma were evaluated by the HDRA method in order to determine its possible usefulness in the treatment of this cancer. All the materials were obtained either during biopsy or surgical excision at our hospital, between January 2003 and October 2005. Results: A significant inhibition rate in primary biopsies was observed with Adriamycin (ADM) (47.3±15.3{\%}); Cisplatin (CDDP) (36.3±22.3{\%}); and Carboplatin (CBP) (50.5±23.3{\%}); treatment. ADM and CBP demonstrated a statistically significant increase in inhibition rates compared to the other drugs. Conclusion: Even though the HDRA method has many limitations, it might be a feasible and useful technique for selecting and predicting the efficacy of anticancer drugs for osteosarcoma patients.",
keywords = "Chemosensitivity, Histoculture drug response assay, Osteosarcoma",
author = "Lee, {By Soo Yong} and Jeon, {Dae Geun} and Cho, {Wan Hyung} and Song, {Won Seok} and Kim, {Moon Bo} and Park, {Jong Hoon}",
year = "2006",
month = "7",
day = "1",
language = "English",
volume = "26",
pages = "2929--2932",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4 B",

}

TY - JOUR

T1 - Preliminary study of chemosensitivity tests in osteosarcoma using a histoculture drug response assay

AU - Lee, By Soo Yong

AU - Jeon, Dae Geun

AU - Cho, Wan Hyung

AU - Song, Won Seok

AU - Kim, Moon Bo

AU - Park, Jong Hoon

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Background: The clinical efficacy of chemotherapy is strongly correlated with the histoculture drug response assay (HDRA) in various types of cancers. However, there have been no previous reports on its use in osteosarcoma. Materials and Methods: Thirty-six fresh samples of human osteosarcoma were evaluated by the HDRA method in order to determine its possible usefulness in the treatment of this cancer. All the materials were obtained either during biopsy or surgical excision at our hospital, between January 2003 and October 2005. Results: A significant inhibition rate in primary biopsies was observed with Adriamycin (ADM) (47.3±15.3%); Cisplatin (CDDP) (36.3±22.3%); and Carboplatin (CBP) (50.5±23.3%); treatment. ADM and CBP demonstrated a statistically significant increase in inhibition rates compared to the other drugs. Conclusion: Even though the HDRA method has many limitations, it might be a feasible and useful technique for selecting and predicting the efficacy of anticancer drugs for osteosarcoma patients.

AB - Background: The clinical efficacy of chemotherapy is strongly correlated with the histoculture drug response assay (HDRA) in various types of cancers. However, there have been no previous reports on its use in osteosarcoma. Materials and Methods: Thirty-six fresh samples of human osteosarcoma were evaluated by the HDRA method in order to determine its possible usefulness in the treatment of this cancer. All the materials were obtained either during biopsy or surgical excision at our hospital, between January 2003 and October 2005. Results: A significant inhibition rate in primary biopsies was observed with Adriamycin (ADM) (47.3±15.3%); Cisplatin (CDDP) (36.3±22.3%); and Carboplatin (CBP) (50.5±23.3%); treatment. ADM and CBP demonstrated a statistically significant increase in inhibition rates compared to the other drugs. Conclusion: Even though the HDRA method has many limitations, it might be a feasible and useful technique for selecting and predicting the efficacy of anticancer drugs for osteosarcoma patients.

KW - Chemosensitivity

KW - Histoculture drug response assay

KW - Osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=33746754741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746754741&partnerID=8YFLogxK

M3 - Article

C2 - 16886615

AN - SCOPUS:33746754741

VL - 26

SP - 2929

EP - 2932

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4 B

ER -